Artificial Life， Inc. has been a pioneer in artificial intelligence and mobile technology since its inception in Boston in 1994. We are a public US corporation (OTC Bulletin Board: ALIF) with listing on the Frankfurt Stock Exchange (Frankfurt: AIF.F; Xetra: AIF.DE) and headquarters and production center in Hong Kong. We have additional offices in Berlin， Germany (EMEA headquarters)， Tokyo， Japan， and Santa Monica， USA. currently our main business areas are: high quality (3D) interactive (massive multiplayer) mobile games， mobile participation television， mobile business applications， our powerful mobile commerce technology platform OPUS-M(TM) and our green IT solutions provided by Green Cortex， Inc. We have won many industry awards for our outstanding technology and products.
Today:HONG KONG and LOS ANGELES， Feb. 14， 2011 — Artificial Life， Inc.， (OTC Bulletin Board: ALIF) (http://www.artificial-life.com)， a leading full service provider of award-winning smartphone and tablet technology and applications， has today celebrated the official launch of its new Alife Blog and Investments Section. while the former is to embrace the tech blogging trend and to give customers and ns regular updates about the Company and its products， the latter is to give companies looking for investments from Artificial Life the investment criteria and to provide an uploading platform for business plans and investment proposals to the Company.
Alife BlogThe new Alife Blog， which is co-authored by Artificial Life (ALIF)'s Chairman and CEO， Eberhard Schoneburg， and his staff， provides a wide range of personal and technical sector view points about the mobile industry for gaming and software. The blog will provide constantly updated posts offering the latest technology insights， gaming industry's trends， and Company news. The blog will also feature regular video posts about Artificial Life's products to explain their functionalities. The postings are casual in style and tone and shall invite customers to interact more closely with the Company and its key representatives.
Investments SectionThe addition of an Investments section to the Artificial Life corporate website will cilitate the business development of the Company's newly established subsidiary， Artificial Life Investments Ltd. Interested companies who are looking for expansion and growth capital from Artificial Life， and who would like to collaborate with a strong， global partner， may upload financial and contact information in the Investments section for Artificial Life to evaluate.
"Sharing information and being transparent to the public are very important aspects of business today. Artificial Life has launched the Alife Blog as well as the Investments section so that we may more readily communicate our insights and better connect with our peers and partners，" said Eberhard Schoneburg， CEO of Artificial Life， Inc.
Based in the city of Yantai， Shandong Province， China， Bohai Pharmaceuticals Group， Inc. (OTCBB/OTCQB: BOPH) is engaged in the production， manucturing and distribution of herbal pharmaceuticals based on Traditional Chinese Medicine in China. Bohai's medicines address common health problems such as rheumatoid arthritis， viral infections， gynecological diseases， cardio vascular issues and respiratory diseases. Bohai's products are sold either by prescription through hospitals or over-the-counter through local pharmacies and retail drug store chains. Bohai has approximately 600 employees， including approximately 300 sales representatives， operating from 20 offices throughout China. Bohai's three lead products， Tongbi Capsules， Tongbi Tablets and Lung Nourishing Cream， are eligible for reimbursement under China's National Medical Insurance Program.
For comprehensive investor relations material， including ct sheets， research reports， presentations and video， please follow the appropriate link: Investor Relations Portal， Investor Fact Sheet and Overview Video. For additional information， please visit Bohai's corporate website: www.bohaipharma.com.
Additional Information Relating to Bohai's Trading DataDue to certain recent disruptions in the marketplace relating to quotations on the OTC Bulletin Board operated by FINRA (OTCBB)， incomplete trading data may exist for certain companies like Bohai. Real-time trading data for Bohai on the OTCQB market is available through the below link. Readers are advised that OTCQB market is operated by the owner of otcmarkets.com， and Bohai Pharmaceuticals Group， Inc. makes no representation or warranty regarding the OTCQB market.
For real-time trading data for Bohai on the OTCQB market， including Level 2 quotes， please visit: www.otcmarkets.com/stock/boph/quote.
News Today:YANTAI， China， Feb. 14， 2011 — Bohai Pharmaceuticals Group， Inc. (OTC Bulletin Board/OTCQB: BOPH)， a China-based pharmaceutical company engaged in the production， manucturing and distribution of Traditional Chinese Medicine (TCM) in China， today reported record financial results for its second quarter of fiscal 2011 ended December 31， 2010.
Summary of Fiscal Second Quarter Ended December 31， 2010 Financial Results:Net Revenues of $22.2 million， an increase of 32% from $16.8 million in 2009Gross profit of $17.5 million， an increase of 24% from $14.2 million in 2009Net income of $6.5 million， an increase of 100% from $3.3 million in 2009Fully diluted EPS of $0.31 and basic EPS of $0.39 for fiscal Q2 2011， compared to $0.25 Q2 2010"During the second quarter， we continued our track record of growth through sales of our three lead TCM products， and our growth was augmented by continued market acceptance of our five new TCM products introduced last year，" said Mr. Hongwei Qu， Chairman， President and CEO of Bohai Pharmaceuticals Group. "During the quarter， we saw our net revenues increase by over 32% compared to the same quarter last year as we reaped the benefits of the strong marketing efforts on our lead products and the continuing the roll out of our newer products. Our efforts to keep administrative costs down have also shown significant benefits to our net income."also during the quarter， in December we were very excited to announce our agreement to acquire 14 approved TCM medicines， which we believe represents a tremendous opportunity for our future sales growth，" continued Mr. Qu. "We believe our continued progress with our sales initiatives， along with the Chinese government's growing support of the TCM industry and our growing product portfolio， put us in a great position to continue driving shareholder value."Bohai is currently authorized by the Chinese government to produce 43 Traditional Chinese Medicine products， of which 15 are currently being produced by the company. Sales in the second quarter were generated mainly from Bohai's lead products， Lung Nourishing Syrup， Tongbi Capsules and Tongbi Tablets， which together represented approximately 67% of Bohai's total net revenues. However， progress has been made on the five products that Bohai introduced in April and may of 2010. although the new product sales only represented less than 6% of total net revenues in the second quarter， the net revenues for the five new products in the quarter ended December 31， 2010 increased by 77% compared to the quarter ended September 30， 2010.
Mr. Qu added， "As we move into 2011， our balance sheet remains strong and we are well situated in the Chinese TCM market with a growing portfolio of government supported products. not only are Bohai's three lead pOTCBB ALIFroducts reimbursable through the National Drug Reimbursement List in China – and therefore not affected by the recent pricing caps – two of them are also partially sheltered from competition. Tongbi Capsules are a 'protected' medicine in China， meaning Bohai is one of the few manucturers permitted to sell the product， and Lung Nourishing Syrup was recently awarded a patent in China that lasts 20 years， allowing Bohai to sell these medicines at a premium. We believe these advantages， together with our strong marketing efforts， create the potential for continued growth for our company."Highlights for the Fiscal 2011 Second Quarter:Net revenues for the second fiscal quarter increased 32% to $22.2 million compared to the same period in 2009. Net revenues for the six months ended December 31， 2010 increased 27% to $39.2 million compared to the same period in 2009.
Sales in the fiscal first quarter were generated mainly from Bohai's lead products， Lung Nourishing Syrup， Tongbi Capsules and Tongbi Tablets， which together represented over 67% of total net revenues.
Net revenues for five new products that were introduced in April 2010 increased from $720，000 for the first fiscal quarter to $1，271，000 for the three months ended December 31， 2010， an increase of 77%.
Acquired 14 new TCM medicines of which 4 are included in China's Essential Drug List (EDL) and an additional 5 included in the National Drug Reimbursement List (NDRL). Inclusion on the EDL or NDRL allows for up to 100% insurance coverage by the Chinese government.
New Chinese healthcare plan seeks to extend national medical insurance coverage to China's rural areas， with a target population in excess of 900 million， and to promote the use of TCM products.
Further implementation of a proactive marketing strategy in the quarter significantly increased revenue on all of the TCM products Bohai currently sells.
Net income for the second fiscal quarter increased 100% to $6.5 million compared to the same period in 2009. Net income from operations increased 47% to $6.4 million. Included in net income was a non-cash gain of $2.9 million for changes in ir value of warrants and non-cash charges for approximately $867，000 for unamortized beneficial conversion of our convertible notes and restricted stock and option based compensations. .
Bohai's focused marketing strategy emphasizes quality products and aggressive sales and marketing efforts along with leveraging the "protected" manucturing status and national insurance coverage for certain pharmaceutical products. Currently， Bohai has nearly 600 employees， including approximately 300 that are engaged in sales and distribution in 20 locations throughout China.
Bohai anticipates its overall net revenues will continue to increase due to a national medical and health plan initiated bytheChinese government in2009， which plan is intended to eventually cover individual health insurance for over 90% of China's population by 2011 and includes traditional Chinese medicines for coverage and reimbursement from hospitals and medical centers all over China.
Earnings Conference Call Details:Bohai will host a conference call Today on Monday， February 14， 2011 at 11:00 a.m. Eastern to discuss its financial results for the second quarter of fiscal 2011 ended December 31， 2010. The teleconference can be accessed by dialing 877-407-8031 when calling within the United States or 201-689-8031 when calling internationally. Please dial in 10 minutes prior to the beginning of the call. there will be a playback available until March 5， 2011. to listen to the playback dial 877-660-6853 when calling within the United States， or 201-612-7415 when calling internationally and use account number: 286， in conjunction with replay ID number: 367173.
The conference call will be simultaneously webcast and available on the company's website， www.bohaipharma.com， under the "Events and Presentations" tab of the "Investors" section.
ProGreen Properties， Inc. (ProGreen) (OTCBB-PGEI) is a young company (2009) based in Birmingham， Michigan. ProGreen is engaged in the business of acquiring， remodeling and upgrading residential real estate into more energy efficient， modern comfortable living spaces. These properties are then marketed as ProGreen Homes. ProGreen believes that Michigan offers some of the best investment opportunities in the presently distressed US property market.
News Today:BIRMINGHAM， Mich.， Feb. 14， 2011 — ProGreen Properties， Inc. ("ProGreen") www.progreenproperties.com， (OTC Bulletin Board: PGEI). ProGreen is pleased to announce that it has signed a Letter of Intent ("LOI") to SolTech Energy Sweden AB ("SolTech") www.SolTechEnergy.com. The basis of the LOI is to commence an in depth evaluation and analysis relating to the prospect of introducing SolTech's unique solar technology and products to the US housing market.
(Logo: http://photos.prnewswire.com/prnh/20101019/CL85266LOGO )SolTech's solar energy technology is unique since representing new roof and/or wall cladding and a solar collector， whereby the south cing part of a roof and/or wall can become one huge thermal solar panel， placed under glass roof tiles and thus creating or maintaining an esthetically appealing look of the building. Because of the large size， massive amounts of energy can be generated， which substantially reduces the cost of energy for heating， as well as the cost of hot water. SolTech is now also， as an add on， developing a system that is able to produce electricity from the same thermal solar energy source when surplus energy is produced， as for example during the summer when heating is not needed. The efficiency of this dual use of the sun as an energy source in one system， is expected to be higher compared to other solar energy solutions， resulting in greater financial returns， as well as in improving the environment.
"We are very excited about this first step towards this new opportunity for ProGreen， as it could not only result in ProGreen implementing a new unique solar application to future real estate projects， but also open the door to possible creating an independent solar division of ProGreen， once the concept has been proven on our own properties，" says Jan Telander， CEO of ProGreen Properties， Inc.
Visit: www.breakthroughstocks.netAbout BREAKTHROUGHSTOCKS.NETBREAKTHROUGHSTOCKS.NET is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable， but not guaranteed to be accurate by BREAKTHROUGHSTOCKS.NET. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell， hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
For additional information， please contact firstname.lastname@example.org， www.breakthroughstocks.net((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to email@example.com)).
Successful Implantation of a Continuous-Flow Total Artificial Heart in a Patient at The Texas Heart Institute at St. Lukes Episcopal Hospital
Godfrey Payton - Surveyors & Valuers - Old Bablake
My Notebook (0)My Notebook (0)UK Business Directory
This Page Took 1.538 secs To Load, Current Template - "shape", Language - "en".
GZip Compression Disabled, 60 SQL Queries Executed, Took 1.186 secs ( Average 0.02 secs )